CELLULAR ONCOLOGY

Scope & Guideline

Fostering Global Collaboration in Oncological Science

Introduction

Delve into the academic richness of CELLULAR ONCOLOGY with our guidelines, detailing its aims and scope. Our resource identifies emerging and trending topics paving the way for new academic progress. We also provide insights into declining or waning topics, helping you stay informed about changing research landscapes. Evaluate highly cited topics and recent publications within these guidelines to align your work with influential scholarly trends.
LanguageEnglish
ISSN2211-3428
PublisherSPRINGER
Support Open AccessYes
CountryNetherlands
TypeJournal
Convergefrom 2011 to 2024
AbbreviationCELL ONCOL / Cell. Oncol.
Frequency6 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressVAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS

Aims and Scopes

CELLULAR ONCOLOGY focuses on the intricate mechanisms of cancer biology, emphasizing the cellular and molecular interactions that drive tumor development, progression, and response to therapy. The journal aims to bridge the gap between basic research and clinical applications, providing insights that enhance our understanding of cancer and facilitate the development of novel therapeutic strategies.
  1. Tumor Microenvironment and Immunology:
    Research exploring the interactions between tumor cells and their microenvironment, including immune cells, stromal components, and extracellular matrix, is a core focus. Studies examine how these interactions influence tumor progression, metastasis, and therapeutic responses.
  2. Molecular Pathways and Targeted Therapies:
    The journal highlights the identification and characterization of key molecular pathways involved in cancer biology. It covers research aimed at developing targeted therapies that exploit these pathways, including studies on gene expression, signaling networks, and resistance mechanisms.
  3. Cellular Mechanisms of Cancer Progression:
    CELLULAR ONCOLOGY publishes studies that elucidate the cellular mechanisms underlying cancer progression, including cell signaling, apoptosis, autophagy, and metabolic reprogramming. This includes investigations into how cancer cells adapt to survive and thrive in hostile environments.
  4. Biomarker Discovery and Clinical Implications:
    The journal emphasizes the discovery of biomarkers for cancer diagnosis, prognosis, and treatment response. Research that translates findings from laboratory studies to clinical settings, aiming to improve personalized medicine approaches, is particularly valued.
  5. Innovative Therapeutic Strategies:
    Research on novel therapeutic strategies, including immunotherapy, gene therapy, and combination treatments, is a major focus. The journal aims to showcase advancements in therapeutic approaches that enhance efficacy and reduce resistance in cancer treatment.
CELLULAR ONCOLOGY is at the forefront of several emerging trends in cancer research, reflecting the evolving landscape of oncology. Recent publications indicate a strong focus on innovative approaches that integrate cutting-edge technologies and novel insights into cancer biology.
  1. Immunotherapy and Immune Microenvironment Modulation:
    There is a growing emphasis on immunotherapy, particularly studies investigating how to modulate the immune microenvironment to enhance anti-tumor responses. Research on immune checkpoint inhibitors and CAR-T cell therapies is increasingly prevalent.
  2. Precision Oncology and Genomic Profiling:
    The trend towards precision oncology is highlighted by studies utilizing genomic and transcriptomic profiling to inform treatment decisions. This includes identifying biomarkers that predict response to specific therapies, reflecting a personalized approach to cancer treatment.
  3. Exosome and Extracellular Vesicle Research:
    Research focusing on exosomes and other extracellular vesicles is on the rise, particularly regarding their roles in intercellular communication, drug delivery, and as biomarkers for cancer diagnosis and prognosis.
  4. Metabolic Reprogramming in Cancer:
    Emerging studies are increasingly exploring the role of metabolic pathways in cancer development and progression. Understanding how cancer cells reprogram their metabolism for survival and growth is gaining traction, with implications for therapeutic targeting.
  5. 3D Culture and Organoid Models:
    The use of 3D culture systems and organoids to study cancer biology and drug responses is trending. These models offer more physiologically relevant platforms for testing therapeutics and understanding tumor behavior compared to traditional 2D cultures.

Declining or Waning

While CELLULAR ONCOLOGY continues to explore a broad spectrum of cancer research areas, certain themes have seen a decline in focus over recent years. This reflects shifts in research priorities and the emergence of new methodologies and topics of interest.
  1. Traditional Chemotherapy Mechanisms:
    Research specifically targeting traditional chemotherapy mechanisms has decreased, as the field increasingly shifts towards understanding targeted therapies and immunotherapy. Studies focusing solely on the mechanisms of classic chemotherapeutic agents are becoming less prominent.
  2. Basic Cell Culture Studies:
    Papers concentrating on basic in vitro cell culture studies without translational implications are less frequently published. The journal now favors studies that integrate clinical relevance and translational research, indicating a waning interest in purely foundational laboratory work.
  3. Single Agent Drug Studies:
    There is a noticeable decline in studies focusing on the effects of single-agent drugs in isolation. The trend is moving towards combination therapies and multi-target approaches, reflecting the complexity of cancer treatment and the need for more effective strategies.
  4. Mechanistic Studies Without Clinical Context:
    Research that explores cancer biology at a mechanistic level without linking findings to clinical outcomes or therapeutic implications has seen reduced emphasis. The journal prioritizes studies that can translate findings into clinical applications.

Similar Journals

TECHNOLOGY IN CANCER RESEARCH & TREATMENT

Pioneering the future of oncology with cutting-edge research.
Publisher: SAGE PUBLICATIONS INCISSN: 1533-0346Frequency: 1 issue/year

TECHNOLOGY IN CANCER RESEARCH & TREATMENT, published by SAGE Publications Inc, is a leading open-access journal dedicated to the intersection of technology and oncology. Since its inception in 2002 and with an impactful transition to open access in 2018, it has garnered attention for its commitment to disseminating groundbreaking research that explores innovative methodologies and technologies in cancer diagnostics and therapeutics. With ISSN 1533-0346 and E-ISSN 1533-0338, the journal is highly relevant in the fields of Cancer Research (Q3), Medicine (Q2), and Oncology (Q3), as indicated by its 2023 category quartiles. Its Scopus rankings further highlight its position within the research community, standing at #186 out of 404 in Medicine and #141 out of 230 in Cancer Research. Through a carefully curated selection of articles, this journal aims to bridge the gap between technological advancement and clinical application, providing a vital resource for researchers, healthcare professionals, and students striving to improve cancer treatment outcomes.

CANCER RESEARCH

Unlocking groundbreaking discoveries in cancer science.
Publisher: AMER ASSOC CANCER RESEARCHISSN: 0008-5472Frequency: 24 issues/year

Cancer Research, published by the American Association for Cancer Research, is a premier journal in the field of oncology, renowned for its commitment to advancing cancer research since its inception in 1941. With an impressive impact factor reflecting its vital role in the field, this journal consistently ranks in the Q1 quartile for both Cancer Research and Oncology, positioning it among the top 7.5% of journals in these categories. The journal serves as a crucial platform for researchers, professionals, and students to disseminate and gain insights into groundbreaking studies that shape our understanding of cancer biology, prevention, diagnosis, and treatment. While it is not an open-access publication, its rigorous peer-review process ensures that only high-quality research is published, thus maintaining a standard of excellence in the scientific community. With a strong legacy and an ever-expanding influence, Cancer Research continues to be essential for anyone dedicated to the fight against cancer, showcasing cutting-edge research that drives scientific discovery and innovation.

Wspolczesna Onkologia-Contemporary Oncology

Exploring New Frontiers in Oncology and Radiology
Publisher: TERMEDIA PUBLISHING HOUSE LTDISSN: 1428-2526Frequency: 4 issues/year

Wspolczesna Onkologia - Contemporary Oncology is a leading open-access journal dedicated to the field of oncology and radiology, published by TERMEDIA PUBLISHING HOUSE LTD since 1999. With its ISSN 1428-2526 and E-ISSN 1897-4309, the journal has established a prominent place in scholarly publishing, contributing significantly to the advancement of cancer research and treatment modalities. Located in Poznań, Poland, it operates within a framework of high academic standards, currently holding a Q3 quartile ranking in Oncology and Q2 in Radiology, Nuclear Medicine, and Imaging for the year 2023. The journal serves as a valuable resource for researchers, medical professionals, and students alike, providing a platform for innovative studies and reviews that drive the clinical application of oncological practices. With its commitment to open access, Wspolczesna Onkologia allows for widespread dissemination of knowledge, ensuring that cutting-edge research is accessible to a global audience, thus bridging gaps in cancer care and fostering collaborative advancements in the field.

CELL BIOLOGY INTERNATIONAL

Transforming Insights into Cellular Applications
Publisher: WILEYISSN: 1065-6995Frequency: 12 issues/year

CELL BIOLOGY INTERNATIONAL is a prestigious academic journal dedicated to the rapidly evolving field of cell biology, publishing high-quality research aimed at understanding cellular processes and their implications in various biological contexts. Published by Wiley, this journal has established its relevance with an H-Index that reflects its robust citation impact and a commendable Scopus Rank of #111 out of 285 in the field of Biochemistry, Genetics, and Molecular Biology, positioning it in the 61st percentile. Although it operates under a traditional subscription model, its influential insights are crucial for researchers, professionals, and students alike who are seeking cutting-edge developments in cellular mechanisms and their applications in medicine. The journal spans contributions dating back to 1993, providing a rich archive of knowledge that continues to shape the discourse within the scientific community. With a strong category ranking of Q3 in Cell Biology and Q2 in Medicine (miscellaneous) as of 2023, CELL BIOLOGY INTERNATIONAL stands as a reliable platform for disseminating transformative science in the cellular domain.

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Unlocking the secrets of cancer biology and therapy.
Publisher: BMCISSN: Frequency: 1 issue/year

The JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, published by BMC, is a leading open-access journal dedicated to advancing the field of cancer research and oncology. Since its inception in 1982, this esteemed journal has fostered innovation and collaboration in the scientific community, as evidenced by its outstanding impact factor and position in the Q1 quartile for both Cancer Research and Oncology categories in 2023. With a proud commitment to disseminating high-quality research, the journal operates under an open-access model, ensuring that findings are readily accessible to researchers, healthcare professionals, and students worldwide. The journal has established a distinguished reputation, ranking 23rd out of 404 in Medicine oncology and 16th out of 230 in Biochemistry, Genetics, and Molecular Biology (cancer research), showcasing its importance and influence in guiding the future of cancer treatment and research. With the aim of bridging experimental and clinical research, this journal invites submissions that push the boundaries of our understanding of cancer biology and therapy.

ONCOGENE

Transforming Cancer Research with Cutting-Edge Studies
Publisher: SPRINGERNATUREISSN: 0950-9232Frequency: 50 issues/year

ONCOGENE is a premier peer-reviewed journal published by SpringerNature, serving as a crucial platform for innovative research within the fields of Cancer Research, Genetics, and Molecular Biology. With an impressive Impact Factor and a distinguished Q1 ranking across major categories, ONCOGENE publishes cutting-edge studies aimed at unraveling the complexities of cancer biology and genetic mechanisms. The journal has been a vital resource for the academic community since its inception in 1987, and it continues to foster rigorous scientific discussions and collaborations. Researchers, professionals, and students can access a wealth of critical insights and advances in cancer genomics and therapeutic approaches, cementing ONCOGENE’s role as a leading voice in the landscape of biomedical research. For comprehensive academic research, ONCOGENE remains an indispensable source of knowledge with contributions that significantly impact the evolution of cancer research and treatment strategies.

Advances in Cancer Biology-Metastasis

Connecting Research to Real-World Impact.
Publisher: ELSEVIERISSN: Frequency: 4 issues/year

Advances in Cancer Biology-Metastasis is an emerging journal published by Elsevier, aimed at advancing our understanding of the complexities of cancer biology, with a specific focus on the mechanisms and pathways related to metastasis. With an E-ISSN of 2667-3940, this journal offers a platform for researchers, professionals, and students in the fields of Cancer Research and Cell Biology to disseminate innovative findings and discuss novel therapeutic approaches. Though currently classified in the Q4 quartile across both Cancer Research and Cell Biology categories, the journal aspires to enhance its impact through rigorous peer review and high-quality publication. Positioned to cover the years from 2021 to 2024, it seeks to bridge gaps in foundational knowledge and promote collaborative research efforts that could pivot the current understanding of cancer metastasis. Researchers are encouraged to take advantage of this platform to advocate for advancements in cancer biology, making significant contributions that can influence both academic and clinical practices.

MOLECULAR CANCER RESEARCH

Exploring Breakthroughs in Cancer Biology
Publisher: AMER ASSOC CANCER RESEARCHISSN: 1541-7786Frequency: 12 issues/year

MOLECULAR CANCER RESEARCH, published by the American Association for Cancer Research, stands as a pivotal journal in the fields of cancer research, molecular biology, and oncology. With an impressive impact factor and recognized as a Q1 journal in its respective categories for 2023, it serves as an essential resource for researchers, professionals, and students aimed at advancing our understanding of cancer mechanisms and therapies. The journal, identified by the ISSN 1541-7786 and E-ISSN 1557-3125, provides a platform for cutting-edge research and clinical applications, emphasizing innovation and collaboration within the scientific community. With its focus on high-quality, peer-reviewed articles, MOLECULAR CANCER RESEARCH is vital for anyone looking to stay abreast of significant advancements in cancer biology and treatment strategies. For more details and to access the journal's content, please visit the publisher's link.

CANCER GENE THERAPY

Exploring Breakthroughs in Cancer Gene Innovations
Publisher: SPRINGERNATUREISSN: 0929-1903Frequency: 12 issues/year

Cancer Gene Therapy, published by SpringerNature, stands at the forefront of research in the fields of cancer research, molecular biology, and molecular medicine. With a robust impact factor reflecting its significant influence—ranking in the Q2 category for cancer research and Q1 for both molecular biology and molecular medicine—it serves as an essential resource for scholars and practitioners alike. Since its inception in 1994, the journal has dedicated itself to advancing the understanding and therapeutic application of genetic innovations in oncology. Notably, it holds distinguished Scopus ranks, placing it among the top tier journals in its categories, underscoring its importance to the scientific community. While open access options are not available, the compelling research published here offers invaluable insights into the latest advancements and strategies in cancer therapy. Engaging with *Cancer Gene Therapy* not only keeps professionals informed but also inspires future innovations in the quest for effective cancer treatments.

Cell Communication and Signaling

Connecting Scientists Through Open Access Discoveries
Publisher: BMCISSN: Frequency: 1 issue/year

Cell Communication and Signaling is a premier peer-reviewed journal published by BMC that has made significant contributions to the fields of biochemistry, cell biology, and molecular biology since its establishment in 2003. As an open access journal, it offers unrestricted access to high-quality research, fostering collaboration and innovation among scientists around the globe. The journal is distinguished by its Q1 ranking in all three relevant categories for 2023, underscoring its critical role in advancing the understanding of cellular communication mechanisms and signaling pathways. Positioned within the United Kingdom, Cell Communication and Signaling has been an invaluable resource for researchers, professionals, and students alike, ensuring that the latest findings are accessible to a diverse range of audiences. With an impressive Scopus ranking—placing it in the top percentiles within its subject areas—this journal continues to set the standard for excellence in the pursuit of understanding complex cellular interactions.